This study also demonstrates that EIF4A3 can control tumourigenic capacity of liver cancer cells in vitro and the in vivo tumour growth in a preclinical HCC model of Hep3B‐induced xenografts by the alteration of the expression and splicing events of key oncogenes such as FGFR4. The gene discussed is FGFR4; the disease is neoplasm.